Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 612

Similar articles for PubMed (Select 16912128)

1.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.

PMID:
16912128
2.

The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.

Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T.

Drug Res (Stuttg). 2015 Jun 30. [Epub ahead of print]

PMID:
26125284
3.

Rice protein hydrolysates stimulate GLP-1 secretion, reduce GLP-1 degradation, and lower the glycemic response in rats.

Ishikawa Y, Hira T, Inoue D, Harada Y, Hashimoto H, Fujii M, Kadowaki M, Hara H.

Food Funct. 2015 Jun 24. [Epub ahead of print]

PMID:
26107658
4.

Intestinal SGLT1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents.

Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, Obokata N, Tsuda-Tsukimoto M, Saito A, Arakawa K, Ueta K, Shiotani M.

J Pharmacol Exp Ther. 2015 Jun 23. pii: jpet.115.225508. [Epub ahead of print]

5.

Sitagliptin improves glycemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.

Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ.

Diabetes Obes Metab. 2015 Jun 12. doi: 10.1111/dom.12507. [Epub ahead of print]

PMID:
26094974
6.

An Overview of Recent Dipeptidyl Peptidase-IV Inhibitors: Linking Their Structure and Physico-Chemical Properties with SAR, Pharmacokinetics and Toxicity.

Smelcerovic A, Miljkovic F, Kolarevic A, Lazarevic J, Djordjevic A, Kocic G, Anderluh M.

Curr Top Med Chem. 2015 Jun 19. [Epub ahead of print]

PMID:
26088350
7.

Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: findings from a national health plan.

Huang X, Liu Z, Shankar RR, Rajpathak S.

Curr Med Res Opin. 2015 Jul 3:1-6. [Epub ahead of print]

PMID:
26073703
8.

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.

Ueno H, Tsuchimochi W, Wang HW, Yamashita E, Tsubouchi C, Nagamine K, Sakoda H, Nakazato M.

Diabetes Ther. 2015 Jun;6(2):187-96. doi: 10.1007/s13300-015-0113-3. Epub 2015 Jun 9.

9.

Glucose-lowering medicines for type 2 diabetes.

Davoren P.

Aust Fam Physician. 2015;44(5):176-9.

10.

Novel 4-Heteroaryl-Antipyrines as DPP-IV Inhibitors.

Gomha SM, Eldebss TM, Badrey MG, Abdulla MM, Mayhoub AS.

Chem Biol Drug Des. 2015 May 29. doi: 10.1111/cbdd.12593. [Epub ahead of print]

PMID:
26032047
11.

Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases.

Nagai H, Fujiwara S, Takahashi Y, Nishigori C.

J Dermatol. 2015 May 28. doi: 10.1111/1346-8138.12955. [Epub ahead of print]

PMID:
26031638
12.

Effects of oral hypoglycemic agents on platelet function.

Papazafiropoulou A, Papanas N, Pappas S, Maltezos E, Mikhailidis DP.

J Diabetes Complications. 2015 Apr 16. pii: S1056-8727(15)00162-2. doi: 10.1016/j.jdiacomp.2015.04.005. [Epub ahead of print] Review.

PMID:
26026848
13.

How attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?

Schernthaner G, Schernthaner-Reiter MH.

Diabetes Obes Metab. 2015 Jul;17(7):613-5. doi: 10.1111/dom.12478. Epub 2015 May 28. No abstract available.

PMID:
26018554
14.

[Modern management with oral antihyperglycemic agents in type 2 diabetes].

Müller-Wieland D.

MMW Fortschr Med. 2015 Mar 26;157 Suppl 1:69-74. doi: 10.1007/s15006-015-2719-9. German. No abstract available.

PMID:
26012992
15.

Design, Synthesis, and Pharmacological Evaluation of Fused β-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors.

Jiang T, Zhou Y, Chen Z, Sun P, Zhu J, Zhang Q, Wang Z, Shao Q, Jiang X, Li B, Chen K, Jiang H, Wang H, Zhu W, Shen J.

ACS Med Chem Lett. 2015 Apr 8;6(5):602-6. doi: 10.1021/acsmedchemlett.5b00074. eCollection 2015 May 14.

PMID:
26005541
16.

Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Zhong J, Maiseyeu A, Rajagopalan S.

Clin Lipidol. 2015;10(1):103-112.

PMID:
26005496
17.

Sitagliptin for Type 2 diabetes: a 2015 update.

Lee M, Rhee MK.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):597-610. doi: 10.1586/14779072.2015.1046840.

PMID:
26000559
18.

Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.

Østoft SH, Bagger JI, Hansen T, Hartmann B, Pedersen O, Holst JJ, Knop FK, Vilsbøll T.

Eur J Endocrinol. 2015 Aug;173(2):205-15. doi: 10.1530/EJE-15-0070. Epub 2015 May 7.

PMID:
25953829
19.

Improvement of glycemic control in streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin hydrolysate as the dipeptidyl-peptidase IV inhibitor.

Hsieh CH, Wang TY, Hung CC, Chen MC, Hsu KC.

Food Funct. 2015 Jun 10;6(6):1887-92. doi: 10.1039/c5fo00124b.

PMID:
25946069
20.

Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults with Impaired Glucose Tolerance.

Best C, Struthers H, Laciny E, Royal M, Reeds DN, Yarasheski KE.

J Clin Endocrinol Metab. 2015 May 4:jc20151531. [Epub ahead of print]

PMID:
25938633
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk